A Randomised tRial of Expedited transfer to a cardiac arrest centre for non-ST elevation ventricular fibrillation out-of-hospital cardiac arrest:the ARREST pilot randomised trial by Patterson, Tiffany et al.
                          Patterson, T., Perkins, G. D., Joseph, J., Wilson, K., Van Dyck, L.,
Robertson, S., ... Redwood, S. R. (2017). A Randomised tRial of Expedited
transfer to a cardiac arrest centre for non-ST elevation ventricular fibrillation
out-of-hospital cardiac arrest: the ARREST pilot randomised trial.
Resuscitation, 115, 185-191.
https://doi.org/10.1016/j.resuscitation.2017.01.020
Peer reviewed version
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.resuscitation.2017.01.020
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at https://www.sciencedirect.com/science/article/pii/S0300957217300412?via%3Dihub. Please refer
to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
  1 
A Randomised tRial of Expedited transfer to a cardiac arrest centre for 1 
non-ST elevation ventricular fibrillation out-of-hospital cardiac arrest: 2 
The ARREST pilot randomised trial  3 
 4 
Tiffany Patterson1 BSc MBBS PhD, Gavin D Perkins2 MD FRCP FFICM FERC, Jubin Joseph1 MA 5 
BMBCh, Karen Wilson1 MSc, Laura Van Dyck3, Steven Roberston3, Hanna Nguyen1, Hannah McConkey1 6 
MA MBBS MRCP, Mark Whitbread4 MSc, Rachael Fothergill4 PhD, Joanne Nevett4 MSc, Miles Dalby5 7 
MD, Roby Rakhit6 MD, Philip MacCarthy7 MD, Divaka Perera1 MD, Jerry P. Nolan8 FRCA FRCP FRCEM 8 
FFICM, Simon R Redwood1 MD FRCP FACC FSCAI 9 
 10 
1. Cardiovascular Division, The Rayne Institute BHF Centre of Research Excellence, King's 11 
College London, St. Thomas' Hospital, London, UK  12 
2. Warwick Clinical Trials Unit and Heart of England NHS Foundation Trust, Warwick Medical 13 
School, University of Warwick, Coventry, UK 14 
3. London School Of Hygiene and Tropical Medicine Clinical Trials Unit, London, UK 15 
4. London Ambulance Service, London, UK 16 
5. Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, Middlesex, UK 17 
6. Department of Cardiology, Royal Free NHS Foundation Trust, London, UK 18 
7. Department of Cardiology, King’s College Hospital NHS Foundation Trust, London, UK 19 
8. School of Clinical Sciences, University of Bristol and Department of Anaesthesia, Royal United 20 
Hospital, Bath, UK 21 
 22 
Short Title: ARREST Pilot Randomised Trial 23 
 24 
Corresponding Author: Simon R Redwood, Professor of Interventional Cardiology, Cardiovascular 25 
Department, Kings College London, St Thomas' Hospital, London SE1 7EH 26 
Email: simon.redwood@gstt.nhs.uk Tel: +44 (0) 207 188 1083 27 
 28 
Total Word Count: 2952 (excl. abstract and references) Disclosure: The authors have no disclosures or conflicts 29 
of interest to share. Keywords: Out-of-hospital Cardiac Arrest, Cardiac Resuscitation Centre, Coronary 30 
Angiography. Acknowledgements: The Pan-London Acute Coronary Syndrome Advisory Group; Advanced 31 
Paramedic Practitioners, London Ambulance Service; Tim Clayton, Laura Van Dyck, London School of Hygiene and 32 
Tropical Medicine Clinical Trials Unit.  33 
Funding: The ARREST pilot randomised trial was funded by an unrestricted educational grant from Zoll Medical, 34 
MA. The authors are solely responsible for study conduct, analysis and drafting and editing of the paper and its final 35 
contents. The full scale RCT has been granted funding by the British Heart Foundation CS/16/3/32615. 36 
  2 
Abstract 37 
 38 
Background 39 
Wide variation exists in inter-hospital survival from out-of-hospital cardiac arrest (OHCA). Regionalisation 40 
of care into cardiac arrest centres (CAC) may improve this. We report a pilot randomised trial of expedited 41 
transfer to a CAC following OHCA without ST-elevation. The objective was to assess the feasibility of 42 
performing a large-scale randomised controlled trial. 43 
 44 
Methods 45 
Adult witnessed ventricular fibrillation OHCA of presumed cardiac cause were randomised 1:1 to either: 46 
1) treatment: comprising expedited transfer to a CAC for goal-directed therapy including access to 47 
immediate reperfusion, or 2) control: comprising current standard of care involving delivery to the 48 
geographically closest hospital. The feasibility of randomisation, protocol adherence and data collection 49 
of the primary (30-day all-cause mortality) and secondary (cerebral performance category (CPC)) and in-50 
hospital major cardiovascular and cerebrovascular events (MACCE)) clinical outcome measures were 51 
assessed.  52 
 53 
Results 54 
Between November 2014 and April 2016, 118 cases were screened, of which 63 patients (53%) met 55 
eligibility criteria and 40 of the 63 patients (63%) were randomised. There were no protocol deviations in 56 
the treatment arm. Data collection of primary and secondary outcomes was achieved in 83%. There was 57 
no difference in baseline characteristics between the groups: 30-day mortality (Intervention 9/18, 50% vs. 58 
Control 6/15, 40%; P=0.73), CPC 1/2 (Intervention 9/18, 50% vs. Control 7/14, 50%; P>0.99) or MACCE 59 
(Intervention 9/18, 50% vs. Control 6/15, 40%; P=0.73). 60 
 61 
Conclusions 62 
These findings support the feasibility and acceptability of conducting a large-scale randomised controlled 63 
trial of expedited transfer to CAC following OHCA to address a remaining uncertainty in post-arrest care.  64 
 65 
Trial Registration: ISRCTN 96585404 66 
 67 
 68 
 69 
 70 
 71 
 72 
 73 
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Introduction 74 
Out-of-hospital cardiac arrest (OHCA) is a global public health issue. There are 60,000 OHCA per year 75 
in the United Kingdom and over 400,000 in the United States.1-3 There is wide variation in both regional 76 
and inter-hospital survival rates from OHCA and overall survival remains poor, with a reported average 77 
of 7%.4 The adoption of systematic approaches to post-resuscitation care may improve long-term survival 78 
from OHCA.5,6 Regionalisation of care into specialist centres has played a vital role in the management 79 
of time-critical illnesses through concentration of services and greater provider experience.7-14 Coronary 80 
artery disease is responsible for >70% of OHCA, with an acute occlusion demonstrated in 50% of 81 
consecutive patients taken immediately to coronary angiography.15 Multi-faceted interventions including 82 
early cardiopulmonary resuscitation (CPR) and defibrillation, followed by timely reperfusion are 83 
associated with reduced risk of re-arrest, reduced myocardial dysfunction and thus improved outcomes 84 
following cardiac arrest from ST-elevation (STE) myocardial infarction.16-18 The International Liaison 85 
Committee on Resuscitation (ILCOR) suggests transport of all post-arrest patients to a cardiac arrest 86 
centre (CAC) with 24/7 access to interventional cardiology facilities to manage the ensuing cardiovascular 87 
dysfunction and to diagnose and treat the underlying cause with a view to increasing survival.19-22 The 88 
management of cardiac arrest survivors without STE, however, is controversial, with a less time-sensitive 89 
approach to cardiac catheterisation. Because of the lack of randomised data, there has been variable 90 
uptake of such a strategy amongst the interventional cardiology community. ILCOR states that 91 
randomised trials are therefore essential in this population to determine if timely delivery to a CAC 92 
improves survival.23 However, the coordination of this is complex and close interaction is necessary 93 
between centres and ambulance services and internally between the emergency department, 94 
cardiologists and the critical care team. We performed A (pilot) Randomised tRial of Expedited transfer 95 
to a cardiac arrest centre for non-ST elevation OHCA (ARREST) of presumed cardiac cause to assess 96 
the safety and feasibility of conducting a large-scale randomised controlled trial in patients without STE. 97 
 98 
Methods 99 
This was a pilot multi-centre prospective randomised controlled trial undertaken in London, United 100 
Kingdom by London Ambulance Service (LAS) and St Thomas’ Hospital (for system characteristics see 101 
online supplemental information). All adult witnessed out-of-hospital pulseless ventricular tachycardia 102 
(VT) or ventricular fibrillation (VF) cardiac arrests without obvious non-cardiac cause (trauma, drowning, 103 
suicide, poisoning) attended by the advanced paramedic practitioners in a pre-hospital setting were 104 
considered eligible for inclusion. Randomisation was performed following 3 cycles of CPR regardless of 105 
return of spontaneous circulation (ROSC). Refractory VF was defined as refractory to shock and drug 106 
treatment following 3 cycles of CPR. Patients were excluded from the trial if at the point of randomisation 107 
they had evidence of STE on the post-resuscitation ECG, the initial rhythm was asystole or pulseless 108 
electrical activity (PEA), a do not attempt resuscitation order was in place or suspected pregnancy. 109 
 110 
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Before randomisation, patient management followed standard pre-hospital ALS guidelines. Eligible 111 
patients were randomly allocated with the use of sequentially numbered opaque, tamper-proof sealed 112 
envelopes (sealedenvelope.com) with pre-assigned random permuted blocks of ten, stratified according 113 
to site (advanced paramedic car). Randomisation was performed 1:1 to one of two parallel trial arms: 114 
intervention or control. The intervention arm consisted of activation of the pre-hospital triaging system 115 
(currently routinely in place for STE patients only) with pre-alert and delivery of the OHCA patient to the 116 
catheter laboratory at the dedicated CAC (24 hours a day, 7 days a week). Patients were transported to 117 
hospital with or without ROSC. Patients who achieved ROSC received guideline-recommended post-118 
resuscitation care including targeted temperature management (36°C 28 hours, followed by gradual 119 
rewarming at 0.5°C per hour)24 and goal-directed therapies. These included evaluation and identification 120 
of the underlying cause of arrest with access to immediate reperfusion if necessary and maintenance of 121 
normocapnia and normoxia with protective ventilation, optimisation of haemodynamics as well as 122 
maintenance of normoglycaemia.25 123 
 124 
The control arm comprised the current standard of pre-hospital care for patients with cardiac arrest of 125 
suspected cardiac aetiology as per LAS Cardiac Care Guidance Protocol (supplemental data). Patients 126 
were conveyed to the closest emergency department and management thereafter followed standard 127 
hospital protocol. In the absence of non-cardiac cause, and in the absence of futility, coronary 128 
angiography was recommended within 48-72 hours in the control arm if not performed sooner (evidence 129 
of STE or high-suspicion of on-going infarction at the discretion of the physician).  130 
 131 
The primary objective of this pilot trial was to assess the feasibility of a randomised trial in OHCA without 132 
STE comparing expedited transfer to a CAC with the current standard of care to assess a difference in 133 
30-day mortality. Feasibility outcome measures included recruitment rate, protocol adherence and the 134 
ability to obtain case-report form specific data on participants. The primary clinical endpoint was 30-day 135 
all-cause mortality. Secondary clinical endpoints comprised 1) good neurological function at discharge, 136 
capped at 30 days according to the cerebral performance category (CPC), the most commonly used post-137 
resuscitation outcome measurement for this purpose.26 2) The composite of in-hospital major adverse 138 
cardiovascular events (MACE) capped at 30 days, defined as: re-infarction27, further revascularisation 139 
and bleeding.  140 
 141 
Prior to data analysis, the following additions were made to the trial secondary outcomes to capture all 142 
adverse events: 1) MACE was modified to include cerebrovascular events – termed MACCE. 2) Sepsis, 143 
defined as two or more components of the systemic inflammatory response syndrome.28 144 
 145 
Trained research staff at St Thomas’ Hospital collected trial related data. The trial was managed and 146 
coordinated by the London School of Hygiene and Tropical Medicine Clinical Trials Unit (LSHTM CTU). 147 
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The study was granted ethical approval by the United Kingdom National Research Ethics Committee 148 
(REC 13/LO/1508). Due to the specific nature of the trial and the immediacy of the intervention, the 149 
committee waived the need for prior informed consent.  At the earliest appropriate time, the participant or 150 
their legal surrogate were asked for delayed consent. The trial was prospectively registered with the 151 
International Standard Randomised Controlled Trials Registry (ISRCTN 96585404). 152 
 153 
Statistical Analysis 154 
Statistical analysis, based on intention to treat, was performed using StatPlus (AnalystSoft, USA) and 155 
Prism version 7.0 (GraphPad Software Inc, USA). The sample size (n=40) was selected to allow an 156 
assessment of the feasibility of recruitment and implementation of trial processes.29 The pilot study was 157 
not powered to detect important differences. However, categorical data were compared using Fisher’s 158 
exact test; continuous data were compared by 2-sample t-test. The treatment groups were compared for 159 
the primary endpoint of all-cause mortality 30-days after randomisation using odds ratios with 95% 160 
confidence intervals (CI). The Kaplan-Meier survival curves were drawn to assess differences between 161 
groups for the time to an event data examining all-cause mortality at 30 days. All p values were 2 sided. 162 
 163 
Results 164 
Patient Population and Feasibility 165 
118 cases were screened, of which 63 patients (53%) met eligibility criteria. Forty of the 63 patients (63%) 166 
were randomised over two separate time periods: November 2014 to March 2015 (10 patients) and 167 
August 2015 to February 2016 (30 patients). Full data were available on 36 patients (90%); reasons for 168 
exclusion are detailed in the patient flow diagram (Figure 1), displayed according to Consolidated 169 
Standards of Reporting Trials (CONSORT) recommendation. The trial was stopped at 40 patients 170 
because the planned sample size to assess trial feasibility was reached. All randomised patients 171 
completed the trial. All patients in the Intervention arm were delivered direct to St Thomas’ Hospital 172 
cardiac catheter lab; patients in the control arm were delivered to the emergency department (ED) in one 173 
of 6 hospitals in London: St. Thomas’ Hospital, St. Mary’s Hospital, Chelsea and Westminster Hospital, 174 
King’s College Hospital, Royal Free Hospital, Royal London Hospital. One patient in the control arm did 175 
not reach hospital (online supplement). After randomisation, 4 patients (10%) were found to meet 176 
exclusion criteria (the presence of ST-elevation on the post-resuscitation ECG). However, for the intention 177 
to treat analysis, all patients were analysed in the group they were randomised to regardless of this or 178 
eventual crossover or other protocol deviation. Only one patient was identified as having a non-cardiac 179 
cause of arrest (end-stage renal failure) and did not survive to hospital. All other patients had a cardiac 180 
cause of arrest. One patient had aortic dissection that was managed within the specialist centre, ten 181 
patients were identified as having a scar-related arrhythmia either due to previous infarct or heart muscle 182 
disease (requiring implantable cardioverter defibrillator implantation on admission) and the rest were 183 
directly due to coronary artery disease.  184 
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 185 
Baseline characteristics, the intervals from cardiac arrest to defined events and ambulance service 186 
interventions are shown in Table 1. There were no significant differences between the two treatment 187 
groups in terms of baseline characteristics and cardiac arrest background variables. All patients 188 
presented with witnessed VF out-of-hospital cardiac arrest. Three patients in each group had ventricular 189 
fibrillation that was refractory to shock and drug treatment and were transported to hospital without ROSC.  190 
 191 
Angiographic characteristics  192 
The coronary angiographic findings are summarised in Table 2. Time to coronary angiography was 193 
shorter in the intervention arm compared with the control arm (100 [75 to 113] versus 132 [93 to 187]; 194 
median difference 32, 95% CI -9 to 101; P=0.08). The incidence of culprit artery occlusion (responsible 195 
for the OHCA) was 44% in the intervention group versus 50% in the control group (OR 0.6, 95% CI 0.1 196 
to 2.3; P=0.7).  197 
 198 
Primary and Secondary Clinical Outcomes 199 
The primary clinical endpoint of 30-day all-cause mortality (Table 3) was similar between both study arms 200 
(Intervention 9/18, 50% vs. Control 6/15, 44%; OR 0.6, 95% CI 0.2 to 2.9; P=0.73). Good neurological 201 
function evaluated at discharge, capped at 30 days, was similar in both groups (Intervention 9/18, 50% 202 
vs. Control 7/15, 47%; OR 1.1, 95% CI 0.3 to 4; P>0.99) (online supplement). The secondary (clinical) 203 
composite endpoint of in-hospital MACCE occurred in 11/18 in the Intervention arm compared with 6/15 204 
in the control arm (61% vs. 53% respectively; OR 1.4, 95% CI 0.4 to 4.9; P=0.73). One stroke occurred 205 
in the control arm, one patient in the intervention arm and two in the control arm underwent further 206 
revascularisation and minor bleeding occurred in one patient in the intervention arm. The secondary 207 
endpoint of 6-month all-cause mortality was 9/17 (53%) in the intervention arm and 6/10 (60%) in the 208 
control arm (OR 0.75, 95% CI 0.2 to 3.8; P>0.99). One third of patients in both groups developed sepsis. 209 
Vascular complications occurred in one patient in the control arm. Four patients in the intervention group 210 
and two patients in the control group required mechanical circulatory support in the form of intra-aortic 211 
balloon pump insertion. Length of stay was the same in the two groups (intervention: 4.5, versus control: 212 
4.5, median difference 0, 95% CI -2 to 8; P=0.19). 213 
 214 
The Kaplan-Meier 30-day survival curve is shown in Figure 2 (intervention versus control: HR 1.7, 95% 215 
CI 0.3 to 10.5; P=0.6). In both study arms, a marked attrition in survival was seen between Day 0 and 216 
Day 4, with 25% of patients dead in the Intervention arm and 17% in the Control arm (overall 21%). No 217 
further patients died between Day 4 and Day 30. Administration of amiodarone was associated with 218 
increased 30-day mortality (HR 11.5, 95% CI 1.04 to 126; P=0.04). Pre-hospital ROSC (HR 0.1, 95% CI 219 
0.01 to 0.7; P=0.02), and cardiac arrest in a public location (HR 0.05, 95% CI 0.004 to 0.45; P=0.01) were 220 
associated with a lower mortality. The performance of coronary angiography was found to negatively 221 
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influence 30-day mortality (HR 0.15, 95% CI 0.03 to 0.71; P=0.02); however, after adjustment for pre-222 
hospital factors, there was no influence on 30-day mortality (HR 0.41, 95% CI 0.05 to 3.5; P=0.4), Figure 223 
3. 224 
 225 
Discussion 226 
We demonstrated that it is possible to complete a randomised controlled trial comparing a pre-hospital 227 
triage system involving delivery of the OHCA patient to a CAC with access to 24/7 interventional 228 
cardiology facilities and receipt of a post-cardiac arrest care bundle with the current standard of care in a 229 
population of OHCA patients without STE. The main finding of this pilot trial is that performing a large-230 
scale randomised controlled trial is safe, feasible and acceptable. The feasibility of randomisation was 231 
demonstrated as follows: (1) recruitment of all adult witnessed shockable OHCA of presumed cardiac 232 
cause exceeded the expected rate. (2) It was possible to set up a fast track, rapid intervention service in 233 
a single CAC 24/7. (3) Protocol adherence was excellent in the intervention arm. (4) Data completeness 234 
was acceptable with documentation of the primary outcome in 83% and secondary outcomes in 80%. 235 
 236 
Based on the findings of the trial pilot, the decision to exclude the refractory cohort from the main trial was 237 
made based on 1) logistical challenges of on-scene extrication, transport and performing coronary 238 
angiography during mechanical CPR (m-CPR). 2) Poor outcomes relative to the cohort of patients 239 
achieving ROSC. 3) The identification that this was a predictor of 30-day mortality. Furthermore, not all 240 
frontline vehicles carry m-CPR devices, which may prevent shock-refractory patients receiving the same 241 
treatment in the main trial. The PARAMEDIC trial (LUCAS m-CPR device) showed a 5% lower survival 242 
rate (significant) in patients with shockable rhythms who received mechanical CPR, although this was not 243 
the primary objective of the trial, and should be interpreted with caution.30 Furthermore, removal of this 244 
cohort will reduce the likelihood of post randomisation identification of STE (10%).  245 
 246 
Outcome was ascertained in 83%; to improve this we will make use of the NHS information centre; in the 247 
PARAMEDIC trial, this enabled 99% follow-up at 30-days.30 Where data cannot be collected in hospital 248 
we plan to make use of the London Ambulance Clinical Audit and Research Unit (CARU) and National 249 
Institute for Cardiovascular Outcomes Research (NICOR). Because of the geographical position of St 250 
Thomas’ Hospital, a large proportion of the standard of care arm were delivered to a CAC; we anticipate 251 
that expanding the trial across London will reduce the proportion of patients in the control arm taken 252 
straight to the cardiac catheterisation laboratory. 253 
 254 
The International Liaison Committee on Resuscitation (ILCOR) suggests transport of all post-arrest 255 
patients to a cardiac arrest centre with 24/7 access to interventional cardiology facilities.19-22 There has 256 
been variable uptake of such a strategy in this cohort; this may be due in part to the lack of randomised 257 
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data, the need for coordination of organised systems of care, and the heterogeneity of the non-STE 258 
population; thus emphasising the need for a randomised controlled trial.  259 
 260 
Our study is consistent with well-established predictors of survival, including ROSC pre-hospital and 261 
cardiac arrest in a public location. The predictor of mortality identified was administration of amiodarone, 262 
this is likely to represent refractory arrhythmia rather than the effect of amiodarone itself. These are 263 
supported by findings in the recently published “amiodarone versus lignocaine and placebo trial in OHCA”, 264 
where no difference in survival was shown, with a higher mortality in those with unwitnessed arrest.31 265 
Coronary angiography was performed in all patients in the intervention group and just under 80% of 266 
control, suggesting that coronary angiography was clinically indicated in the latter. The time to coronary 267 
angiography was shorter in the intervention arm because of immediate delivery to a CAC, but this did not 268 
reach statistical significance in these few patients. In those who underwent coronary angiography, 269 
significant coronary disease was identified in two thirds of patients, with a culprit lesion in just over half, 270 
which is consistent with published registry data.16,32 However should be interpreted with caution because 271 
this was a small patient cohort that may not be representative of the patient population. The findings from 272 
this pilot also suggest that the absence of STE on the post-arrest ECG does not exclude acute ischemia.15 273 
The overall mortality, albeit low, is representative of the VF OHCA population that achieves ROSC pre-274 
hospital and is consistent with previous figures published by the London Ambulance Service. 33 275 
 276 
Limitations 277 
This study was a pilot randomised trial to demonstrate safety and feasibility; the study was not powered 278 
to show a difference in 30-day mortality, neurological endpoints or the composite of in-hospital MACCE. 279 
The full planned trial with a sample size of 860, will aim to address these questions. The catchment area 280 
around St Thomas’ Hospital was small and may not be representative of the population. Although this 281 
pilot provided an indication of the underlying event rate and incidence of occlusive coronary artery 282 
disease, the effect size and therefore sample size calculations were based on a combination of studies. 283 
These included the above pilot findings, Pan-London Annual OHCA audit data, published registry data 284 
(incidence of occlusive disease in OHCA in absence of STE) and randomised trials of reperfusion 285 
therapy.13,33-35 Based on findings from the trial pilot, inclusion criteria were amended to remove the shock-286 
refractory cohort from the main trial because logistical challenges of managing these patients, and in 287 
order to reduce the likelihood of post-randomisation identification of STE. Delayed prognostication (≥72 288 
hours) to prevent the premature withdrawal of life-sustaining treatment was not formally instituted in the 289 
pilot as this was not the current standard of care; however this will be mandated during the full trial.36  290 
 291 
Conclusions 292 
This pilot study demonstrated that a large-scale randomised trial comparing the delivery of a cardiac 293 
arrest patient without STE to the catheter laboratory at a dedicated cardiac arrest receiving centre with a 294 
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view to immediate reperfusion and delivery of post-resuscitation care, compared with standard care, is 295 
safe and feasible. 296 
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Figure 1 417 
 418 
 419 
Table 1 420 
Table 1. Angiographic characteristics of the intervention and control arm. 421 
 Total Intervention Control P value 
Baseline characteristics 
Age (years) 61±15 60±17 61±14 0.77 
Male 31/36 (86%) 15/18 (83%) 16/18 (89%) >0.99 
Hypertension 15/36 (42%) 8/18 (44%) 7/18 (39%) >0.99 
Hypercholesterolemia 14/36 (39%) 8/18 (44%) 6/18 (33%) 0.73 
Diabetes 6/36 (17%) 4/18 (22%) 2/18 (11%) 0.65 
Previous myocardial infarction 8/36 (22%) 5/18 (28%) 3/18 (17%) 0.69 
Previous PCI 5/36 (14%) 2/18 (11%) 3/18 (17%) >0.99 
Previous CABG 3/36 (8%) 2/18 (11%) 1/18 (6%) >0.99 
Ethnicity     
   Caucasian 16/36 (44%) 8/18 (44%) 8/18 (44%) >0.99 
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 Total Intervention Control P value 
   Asian 3/36 (8%) 1/18 (6%) 2/18 (11%) >0.99 
   Afro-Caribbean 0/36 (0%) 0/18 (0%) 0/18 (0%) >0.99 
   Other 4/36 (11%) 2/18 (11%) 2/18 (11%) >0.99 
   Unknown 5/36 (36%) 7/18 (39%) 6/18 (33%) >0.99 
IHD 11/36 (31%) 6/18 (33%) 5/18 (28%) >0.99 
Smoking history 7/36 (19%) 4/18 (22%) 3/18 (17%) >0.99 
Event Characteristics 
Preceding symptoms 12/36 (33%) 8/18 (44%) 4/18 (22%) 0.29 
Public 29/36 (81%) 14/18 (78%) 15/18 (83%) >0.99 
Bystander CPR 22/36 (61%) 10/18 (56%) 12/18 (67%) 0.73 
Presenting rhythm VF 36/36 (100%) 18/18 (100%) 18/18 (100%) >0.99 
Refractory VF 6/36 (17%) 3/18 (17%) 3/18 (17%) >0.99 
LAS Interventions 
Shock required 36/36 (100%) 18/18 (100%) 18/18 (100%) >0.99 
Time to ROSC, mins 18 (8 to 31) 16 (6 to 29) 19 (8 to 36) 0.49 
Duration of resuscitation, mins 19 (7 to 31) 17 (7 to 33) 19 (7 to 31) 0.79 
Number of shocks 4 (2 to 9) 3 (1 to 8) 4 (2 to 9) 0.73 
Amiodarone required 20/36 (56%) 11/18 (61%) 9/18 (50%) >0.99 
Amidoarone dose, mg 0 (0 to 300) 300 (0 to 300) 0 (0 to 300) 0.69 
Adrenaline required 21/36 (58%) 11/18 (61%) 10/18 (56%) >0.99 
Adrenaline dose, mg 1 (0-6) 1 (0 to 8) 2 (0 to 6) 0.75 
Pre-hospital ROSC 28/36 (78%) 14/18 (78%) 14/18 (78%) >0.99 
Intubated 15/36 (42%) 10/18 (56%) 5/18 (28%) 0.18 
GCS on arrival 3 (3 to 10) 3 (3 to 4) 4 (3 to 14) 0.19 
Mechanical CPR 17/36 (47%) 9/18 (50%) 8/18 (44%) >0.99 
ECG characteristics 
12 lead 27/36 (75%) 13/18 (72%) 14/18 (78%) >0.99 
ST elevation 4/36 (11%) 3/18 (17%) 1/18 (6%) 0.6 
 422 
 423 
Table 2 424 
Table 2. Angiographic characteristics of the intervention and control arm. 425 
 Total Intervention Control P value 
Angiogram 32/36 (89%) 18/18 (100%) 14/18 (78%) 0.10 
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 Total Intervention Control P value 
Time to Angiography (minutes)  100; 75–113 132; 93–187 0.08 
Coronary Artery Disease (>50% stenosis) 20/32 (63%) 12/18 (67%) 8/14 (57%) 0.72 
Number of diseased vessels     
0 10/32 (31%) 6/18 (33%) 4/14 (21%) >0.99 
1 4/32 (13%) 2/18(11%) 2/14 (14%) >0.99 
2 4/32 (13%) 2/18(11%) 2/14 (14%) 0.47 
≥3 12/32 (38%) 8/18 (44%) 4/14 (29%) 0.47 
Unknown 2/32 (6%) 0/32 (0%) 2/14 (6%) 0.18 
Culprit: Revascularisation 15/32 (47%) 8/18 (44%) 7/14 (50%) 0.71 
1. PCI 13/15 (87%) 7/8 (88%) 6/7 (86%) >0.99 
LMS 0/13 (0%) 0/7 (0%) 0/6 (0%) >0.99 
LAD 5/13 (38%) 3/7 (43%) 2/6 (33%) >0.99 
Cx 3/13 (23%) 1/7 (14%) 2/6 (33%) 0.56 
RCA 5/13 (38%) 3/7 (43%) 2/6 (33%) >0.99 
2. CABG 2/15 (13%) 1/8 (13%) 1/7 (14%) >0.99 
 426 
 427 
Table 3 428 
Table 3. Primary and secondary outcomes, length of stay and other in-hospital complications 429 
described overall and for both arms of the trial. 430 
 Total Intervention Control OR (95% CI)a P value 
Primary endpoint      
30-day all cause mortality 15/33 (45%) 9/18 (50%) 6/15 (40%) 0.6 (0.2–2.9) 0.73 
Secondary endpoints      
CPC 1/2 at 30 days 16/32 (50%) 9/18 (50%) 7/14 (50%) 1.0 (0.3–3.6) >0.99 
MACCE* 19/33 (58%) 11/18 (61%) 8/15 (53%) 1.4 (0.4–4.9) 0.73 
Death 15/33 (45%) 9/18 (50%) 6/15 (40%) 0.6 (0.2–2.9) 0.73 
MI 0/33 (0%) 0/18 (0%) 0/15 (0%) N/A >0.99 
Further revascularization 3/33 (9%) 1/18(6%) 2/15 (13%) 0.4 (0–3.7) 0.58 
Stroke 1/33 (3%) 1/18 (6%) 0/15 (0%) N/A >0.99 
Bleeding 1/33(3%) 1/18 (6%) 0/15 (0%) N/A >0.99 
Vascular complications 1/33 (3%) 0/18 (0%) 1/15 (7%) 0 (0–7.5) 0.5 
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 Total Intervention Control OR (95% CI)a P value 
6-month all cause mortality 15/27 (56%) 9/17 (53%) 6/10 (60%) 0.75 (0.2–3.8) >0.99 
Length of staya 4.5 (0–11) 4.5 (0–7.3) 4.5 (0–19) 0 (−2 to 8) 0.19 
CPR related complications 1/33 (3%) 1/18 (6%) 0/15 (0%) N/A >0.99 
Renal replacement therapy 2/33 (3%) 1/18 (6%) 1/15 (7%) 0.8 (0–17) >0.99 
Sepsis 11/33 (33%) 6/18 (33%) 5/15 (33%) 1.0 (0.2–4.5) >0.99 
Mechanical circulatory support 6/33 (18%) 4/18 (22%) 2/15 (13%) 1.6 (0.3–9.5) 0.68 
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Figure 2 433 
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Figure 3 436 
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